Data shows IMMU 132 stabilises range of Solid Cancers-Immunomedics

Immunomedics has reported that 71% of patients (34 of 48) with diverse metastatic Solid Cancers had durable disease stabilization after receiving treatments with the Company's novel investigational antibody-drug conjugate (ADC), IMMU 132. These include 7 patients (15%) with Colorectal, Small-Cell and Non-Small-Cell Lung, Oesophageal, and triple-negative Breast Cancers showing partial responses with tumor shrinkage of 30% or more as measured by computed tomography (CT). This seems consistent with the broad increased expression of the target antigen, TROP-2, in most epithelial cancers, commented Cynthia L. Sullivan, President and Chief Executive Officer.

Even after failing multiple prior therapies, a median time to progression of at least 12.6 weeks (range 6.0-51.4 weeks) was observed in 48 patients with at least 1 CT assessment. One patient with hormone-refractive prostate cancer has a long-term, durable stable disease response, which is approaching a year. This patient has received 30 doses of IMMU-132 and treatment is continuing. Despite repeated dosing, no antibodies against the ADC, neither to the antibody nor to SN-38, have been detected in this or any other patients. A total of 69 patients with a median of 3 prior therapies have been enrolled into the multicenter trial, including 13 patients with pancreatic cancer. Data were presented at ASCO.